Free Trial
Invest Smarter with A.I. PowerGet 30 Days Free

Northwest Biotherapeutics (OTCMKTS:NWBO) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?

Written by MarketBeat
September 25, 2025
Northwest Biotherapeutics logo with Medical background

Key Points

  • Northwest Biotherapeutics' stock price has fallen below its 200-day moving average of $0.26, trading as low as $0.25 with a market cap of $378.07 million.
  • The company reported earnings of ($0.01) per share and revenue of $0.13 million for the last quarter, indicating ongoing financial struggles.
  • Northwest Biotherapeutics develops personalized immune therapies for cancer, utilizing its DCVax platform technology to enhance the body's immune response against tumors.
  • Interested in Northwest Biotherapeutics? Here are five stocks we like better.

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.26 and traded as low as $0.25. Northwest Biotherapeutics shares last traded at $0.25, with a volume of 925,503 shares trading hands.

Northwest Biotherapeutics Trading Up 0.6%

The business has a 50 day simple moving average of $0.25 and a two-hundred day simple moving average of $0.26. The stock has a market cap of $378.07 million, a price-to-earnings ratio of -4.16 and a beta of -1.14.

Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The biotechnology company reported ($0.01) earnings per share for the quarter. The business had revenue of $0.13 million during the quarter.

About Northwest Biotherapeutics

(Get Free Report)

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Northwest Biotherapeutics Right Now?

Before you consider Northwest Biotherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Northwest Biotherapeutics wasn't on the list.

While Northwest Biotherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover
Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.